Jacqueline L. Egger

METEOR-1: A phase I study of GSK3326595, a first-in-class protein arginine methyltransferase 5 (PRMT5) inhibitor, in advanced solid tumours

L.L. Siu, Drew Rasco, S. P. Vinay et al. · Annals of Oncology · 2019 · 133 citations · Full text

Medicine, Oncology, Pharmacology +5

Phase I/II study of the clinical activity and safety of GSK3326595 in patients with myeloid neoplasms

Justin M. Watts, Mark D. Minden, Kimo Bachiashvili et al. · Therapeutic Advances in Hematology · 2024 · 30 citations · Full text

Medicine, Oncology, Pharmacology +17

Abstract CT038: A phase I, open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of GSK3326595 in subjects with solid tumors and non-Hodgkin's lymphoma

Drew Rasco, Anthony W. Tolcher, Lillian L. Siu et al. · Cancer Research · 2017 · 16 citations

Medicine, Oncology, Pharmacology +16

Phase I Study of Belantamab Mafodotin in Combination with Standard of Care in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Dreamm-9 Updated Interim Analysis

Saad Z. Usmani, Michał Mielnik, Mamta Garg et al. · Blood · 2024 · 10 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16